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Abstract Geographical information systems (GIS) have
emerged as a group of innovative software components
useful for projects in epidemiology and planning in Health
Care System. This is an original study to investigate
environmental and geographical influences on epidemiol-
ogy of acromegaly in Brazil. We aimed to validate a
method to link an acromegaly registry with a GIS mapping
program, to describe the spatial distribution of patients, to
identify disease clusters and to evaluate if the access to
Health Care could influence the outcome of the disease.
Clinical data from 112 consecutive patients were collected
and home addresses were plotted in the GIS software for
spatial analysis. The buffer spatial distribution of patients
living in Brasilia showed that 38.1 % lived from 0.33 to
8.66 km, 17.7 % from 8.67 to 18.06 km, 22.2 % from
18.07 to 25.67 km and 22 % from 25.68 to 36.70 km dis-
tant to the Reference Medical Center (RMC), and no
unexpected clusters were identified. Migration of 26
patients from 11 others cities in different regions of the
country was observed. Most of patients (64 %) with ade-
nomas bigger than 25 mm lived more than 20 km away
from RMC, but no significant correlation between the
distance from patient’s home to the RMC and tumor
diameter (r = 0.45 p = 0.20) nor for delay in diagnosis
(r = 0.43 p = 0.30) was found. The geographical
distribution of diagnosed cases did not impact in the
latency of diagnosis or tumor size but the recognition of
significant migration denotes that improvements in the
medical assistance network are needed.
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Introduction
The development of pituitary adenomas may be related to
several pathophysiological factors that have been described
in recent years. Although the exactly causative mechanisms
involved remain elusive, they might include genetic and
epigenetic aspects, resulting in cell cycle disruption, cell
signaling abnormalities, oncogene activation, loss of tumor
suppressor activity, and receptor and hormone signaling
dysfunction [1–5].
Despite the advances in comprehension of mechanisms
involved in the development and morbidity of somato-
tropinomas [6–15], the influence of environmental and
socioeconomic factors in the outcome of acromegaly has
not yet been properly evaluated [16]. The recognition of
regional aspects and geographical distribution of diagnosed
cases may help to identify probable clinical case location,
and to describe epidemiological data.
The frequency of pituitary tumors is not well estab-
lished, and most of them are under diagnosed. A met-
analysis suggested a frequency in general population in the
USA, of 14.4 % e 22.5 % in autopsy and radiological
series respectively [17] and prevalence of 190–280 cases/
million [18]. An european study have shown a presence of
clinically relevant pituitary adenomas in 1:1,064 inhabit-
ants [19]. The prevalence of acromegaly in different
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multicentric and international registries is around 60 cases
per million [20–22]. In Brazil there is no published national
database registry for the disease, but in the study region,
the population is around 2,562,963 inhabitants, the
expected number of cases should be around 150 patients
diagnosed in Brasilia. We describe a representative cohort
of 112 patients, in regular medical care in our medical
center.
In recent years, geographical information systems (GIS)
have emerged as a group of innovative and important
software components of many projects in public health and
epidemiology [23]. The usage of GIS tolls in health sci-
ences provides scientific and accurate ways to register,
analyze, and map disease information. GIS tools include
processing geographic data, topographic databases, satellite
remote sensing imagery, among other databases, to create
maps and to cross-correlate public health registries and
other clinical records to environmental factors. This data
analysis scheme may lead into the investigation of the
relation of clinical aspects to the mentioned geographical
parameters, and to describe disease variables and inter-
relationships based on its observed spatial distribution [24,
25]. It may also be useful in disease surveillance based in
the identification of possible spatial clusters of disease
occurrence [26] and to aid planning strategies to improve
regional health care [27–29].
Until now, the use of GIS has not been applied to
pituitary tumors, hence the methodology is novel and the
study represents a proof of principle with this mapping
technique, to evaluate geographical pattern of acromegaly
distribution in Brazil.
Regional and socioeconomic aspects
Brasilia is located around the middle of the polygon that
defines the Federal District of Brazil, at an altitude more
than 1,000 m over the sea level. The city was constructed
in 1960, and planned to be similar to an airplane shape,
with thirty others administrative regions, called satellite
cities, located around the center and in the vicinities of the
limits of the district. Most of the population lives in the
western portion of the Federal District and there is a poorly
populated rural area in the eastern part of the region. In this
region, geochemical anomalies and occurrence of ores with
radioactive components were not identified, comparing to
the rest of Brazilian soil [30, 31]. The Federal District is
not a region rich in industrial or environmental contami-
nants. A recent study conducted by the University of
Brasilia evaluated the concentration of chemical elements
in an important watershed of the Federal District. It was
shown the absence of manganese and copper in the water,
excluding the possibility of water contamination from
industrial activities in the study area [32].
According to Brazilian Census 2010 [30], the population
of the Brasilia area represents a completely heterogeneous
sample of an almost unbiased population, composed by
several ethnic origins and people that have migrated from
several different regions of the country, to built the planned
city, that was recently constructed in a previously inhabited
rural area of the country. The economics conditions of the
main city (Brasilia) are privileged, but considering the
Federal District as whole, the population is basically
composed of middle- and working-class Brazilians [30].
The local public health system is composed by a network
of health posts for primary health care, hospitals dedicated
to secondary care, and two hospitals for tertiary care. Most
of patients with diagnosis of neuroendocrine disorders are
referred to our center. The spatial analysis was applied in
order to investigate possible trends in Acromegaly in a
representative cohort of the Brazilian population, using a
tool that was firstly applied to pituitary tumours.
Objectives
The aims of this study were (1) to demonstrate and validate
a method to link acromegaly registry data with a GIS
mapping and analysis program; (2) to describe the spatial
distribution of acromegaly in the study region in order to
identify the presence of disease clusters; and (3) to analyze
the difficulties of access to Health Care System and its
impact in latency for diagnosis and tumor size.
Methods
Referral medical center (RMC)
The University Hospital of Brasilia is a RMC and belongs
to the tertiary care network of the Federal District. The
Neuroendocrine Unit is a referral center for treatment of
pituitary diseases in the central region of Brazil and
maintains a registry of all patients with pituitary tumors
diagnosed since 1995. All clinical information is updated
periodically using electronic medical records.
Geographical region of interest
Brasilia is a planned city, located in the center-western
region of Brazil, constructed in 1960 to be the national
capital. It is part of the Federal District of Brazil, which
population is comprised of people that have migrated from
several remote regions of the country in the past 50 years.
So, demographic studies show that the current population
of the Federal District represents a sample of a completely,
and maybe unique, multiracial group. Information on the
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socioeconomic conditions concerning this region were
provided by the Brazilian Institute of Geography and Sta-
tistics (IBGE) and the data collected from the most recent
Brazilian Census, 2010 [30, 31].
Acromegaly registry data
Patient data were obtained by examining the Neuroendo-
crine Unit electronic medical records using a proper com-
mercially available software tool (Access, Microsoft,
Bellevue, WA), and a locally developed computer pro-
gram, designed to collect significant information related to
pituitary function and disease. All patients with diagnosis
of acromegaly who had a clinic visit, surgery or radio-
therapy on this unit, in the time range from 1995 to 2013,
were included. Patient variables considered were address,
age, sex, signs and symptoms at diagnosis, comorbidities,
as well as all other data concerning laboratorial and
radiological findings. The study was performed in accor-
dance with the declaration of Helsinki, and was approved
by the local ethics committee.
Application of acromegaly registry data to GIS
mapping tool
The Brasilia acromegaly registry data was incorporated
into a spreadsheet usable format (Excel 2003, Microsoft,
Bellevue, WA). These data were converted to a database
file structure for input to the chosen GIS software (namely,
ArcGIS version 9.3, ESRI, Redlands, CA). The residential
addresses reported by participants in the past 10 years prior
to diagnosis were selected for the spatial analysis. The
address information for cases in which residency time in
the Federal District began after the diagnosis were
excluded. Geocoding parameterization was used in order to
obtain coordinates of the home address of each patient. To
ensure protection of the privacy of individuals, as recom-
mended from Health Insurance Portability and Account-
ability Act (HIPAA) and IOM privacy regulations [33–35],
and to avoid misrepresentation in our data, the chosen scale
of the maps was 1:300,000 and no geocodes (latitude and
longitude) were shown. This way, each point representing
the residence of an individual, includes a larger area,
including at least 15,000 people. The maps were then
generated placing residences in a non-disclosed grid, using
a proper map scale that would not display streets or indi-
vidual residences, and preserve individual confidentiality.
Table 1 Symptoms at diagnosis in patients with acromegaly categorized by tumor size and invasiveness before treatment
Symptoms at diagnosis Size of pituitary tumors Invasive p
Microadenomas Macroadenomas
Symptoms
Headaches 7 31 16 0.01*
Visual impairement 6 18 9 0.02*
Sweatness 8 17 9 0.40
Soft tissue 78 97 90 0.60
Artralgias 9 22 13 0.02*
Galactorrhea 1 8 2 0.25
Hypogonadism 5 17 5 0.10
Co-morbidities
Diabetes mellitus 3 9 8 0.20
Hypertension 6 17 10 0.10
The p values, were calculated by analysis of variance (ANOVA)
* The p values were considered statistically significant if \ 0.05
Fig. 1 Relation between age distribution at first medical evaluation
and year of diagnosis
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Statistics
All results were expressed in mean or median, the indi-
vidual groups of patients were compared and, whenever
applicable, the Pearson correlation coefficient was calcu-
lated. Student’s t test was performed for the comparative
analysis of quantitative variables. The Fisher exact test was
used to compare frequencies and determine associations
between categorical variables. All statistical analyses were
conducted using the Statistical Package for Social Sciences




The cohort was composed of 112 patients, diagnosed in our
center from January 1995 to January 2013. The gender
distribution was 47.3 % women, and 52.7 % men. The
mean age at diagnosis was 42.1 years (ranging from 14 to
70), and 60.4 % of patients had their age ranging between
31 and 60 years old at the first endocrine evaluation. The
most frequent symptoms and co-morbidities are described
on Table 1 compared to tumor size and invasiveness.
Delay for diagnosis
The mean delay time between first symptoms and diagnosis
was 5.8 years (original data ranging from 4 to 9 years), and
the median was 5 years. The older patients presented
longer duration of symptoms preceding diagnosis
(p = 0.003 r = 0.73). For patients who referred to live
outside the Federal District by the time of diagnosis, the
mean delay time was 6.8 years, and the computed data
median was 7 years. In most patients, the disease was
identified in the last 10 years, and for 29.2 % of the
patients, the disease was diagnosed from 2007 to 2013.
Despite better tools for precocious diagnosis, we found that
the age pattern at the diagnosis did not improve along time
(Fig. 1).
Fig. 2 Patients’ home distance to referral clinical center. Buffer distances are represented in five zones from 5 to more than 50 km long, and
patients’ clusters in different colors according to region. GIS software (ArcGIS version 9.3, ESRI, Redlands, CA). Map scale 1:300,000
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Application of geographical information system
Spatial analysis of cohort of patients
The Federal District was represented in buffers corre-
sponding to the radial distance to medical care unit. Five
zones were segmented each 10 km away from the RMC.
The analysis of buffer distribution showed that 38.1 % of
patients lived from 0.33 to 8.66 km, 17.7 % from 8.67 to
18.06 km, 22.2 % from 18.07 to 25.67 km, and 22 % from
25.7 to 36.7 km distant to the RMC (Fig. 2). For this
analysis we considered patients living in the Federal Dis-
trict 10 years prior to diagnosis. No unexpected clusters
were found. The highest concentrations of patients corre-
sponded to areas with higher population density.
For the spatial analysis, from the 112 initial records,
24 % were left unmatched, related to incorrect information
of the address location. Most of these errors were identified
to be due to abbreviated street names, inadequate house
numbers, and county location. Some unmatched records
corresponded to patients living in distant regions of the
country, but referred a local address to benefit from the
health services in Brasilia. Those addresses were reviewed
and correctly matched to the residence addresses by the
time of the diagnosis. Twenty-six patients had a fixed
residency, 10 years prior to diagnosis, located in 11 cities
from different regions of the country, and have migrated to
Brasilia to look for attendance at the Neuroendocrine Unit
of the University Hospital of Brasilia (Fig. 3).
Tumor volume and distance to the referral medical center
The frequency of microadenomas was not different among
the two genders (p = 0.80). Women presented macroade-
nomas more frequently (p = 0.03), and invasive lesions
were more common in men (p = 0.01). Microadenomas
corresponded to 22.3 % of cases and 43.8 % of patients
had invasive lesions by diagnosis.
The patients were represented by different colors and
plotted in a map, according to their tumor larger diameter
at diagnosis. The map was divided in 5 buffer zones
ranging from 5 km to more than 50 km. Sixty-four percent
Fig. 3 Map of pattern of migration of patients from other regions in Brazil, that looked for assistance at Neuroendocrine Unit of the University
Hospital of Brasilia
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of patients with macroadenomas bigger than 25 mm of
maximum tumor diameter lived more than 20 km away
from the RMC (Fig. 4). There was no significant correla-
tion between tumor size and distance to the hospital
(r = 0.45 p = 0.20).
There was no significant correlation between the latency
for diagnosis and the distance from the patient0s home
address to the RMC (r = 0.43 p = 0.3), even considering
the patients living out of the Federal District.
Discussion
In our survey, we verified that the most invasive lesions
were found in younger patients, and in cases of FIPA,
corresponding to previous studies which found a higher
potential of aggressiveness in these patients [4, 36]. The
delay time between the onset of symptoms, and the rec-
ognition of the disease was shorter than usually described
[37, 38]. It is possible that once the disease was suspected,
the patients had easily been routed to our institution, which
is a referral to neuroendocrine pathologies, and this may
have reduced the time for definitive diagnosis. It is also
remarkable that the diagnosis of acromegaly has risen in
the last years in our center, which may reflect the concern
of the local general practitioner physicians, and regional
endocrinologists, to identify and refer these patients to our
center. An improved local knowledge may be related to a
larger number of talks of endocrinologists from our group
in other local institutions, as well as the result of a better-
structured endocrinology syllabus in the main medical
school of Brasilia, which is related to our center.
Fig. 4 Spatial distribution of patients according to the maximal tumor diameter and distance to reffered medical center. GIS software (ArcGIS
version 9.3, ESRI, Redlands, CA). Map scale 1:300,000
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Despite the diagnostic tools and medical information about
the disease, the age by diagnosis did not reduce along decades.
Curiously, we observed that in 80’s and early 90’s the mean
age at diagnosis was younger than in recent years, probably
because at that time, only the patients with more aggressive
tumors reached the medical health care in our city.
Regarding to GIS mapping, this is the first study known
to us which uses this method to evaluate the epidemiology
of acromegaly. So, we are still not aware of all possible
applications of our results. It is possible that environmental
features may influence the appearance and evolution of the
disease. Cannavo` et al. [16] showed a higher prevalence of
this infirmity in a highly polluted area in Italy. The Federal
District of Brazil is an administrative area, with low con-
centration of dangerous environmental hazardous sources.
The vast majority of patients live in urban neighborhood,
which includes mostly small apartment buildings and
houses, and none of them worked previously in industries or
large farms. So, the population described in this study was
homogeneously urban, with comparable socio-cultural
conditions and reasonable access to medical system. All
georreferenced areas considered the patient’s addresses in
the past 10 years prior to diagnosis, including those located
out of the Federal District. In this study, we did not identify
environmental factors that could influence the occurrence of
acromegaly. GIS tools offer a visual way to identify clus-
ters, and in our survey no unexpected clusters were found.
In oncology, GIS has been used with promising results.
Spatial epidemiology using individual level data from
population-based studies may bring forth new exposure
hypothesis. GIS analysis of cancer may reveal inducing
factors and give clues for possible prevention measures
[39, 40]. Although we found no differences related to the
spatial distribution of acromegaly in the Federal District,
variations may emerge while applying the GIS techniques
to a larger cohort of patients. GIS mapping is also a useful
method for planning health care assistance. Patients from
different states looked for attendance in our center, sug-
gesting that delivery of Brazilian health care may improve
with proper location of new health centers in the most
needed areas. GIS mapping may also be an important tool
while planning future centers for medication distribution in
areas that lack proper public health care.
Conclusion
GIS is a reliable method to evaluate the mapping of acro-
megaly in different ways related to the spatial distribution
of the disease. In the future, it may provide guidance for
comprehension of environmental features that might affect
the pathogenesis of the pituitary tumors. GIS can also help
Health Systems in their mission to improve assistance. Our
work shows an example of a useful application of GIS
analysis applied to data sets now available in electronic
medical records. Even though we could not pinpoint a
definite link between the occurrence of acromegaly and the
local environmental problems, we showed that, with the
properly organized medical records, it is possible to iden-
tify health diagnosis patterns and propose local improve-
ments in the medical assistance network. It is the first to
evaluate if the access to health care could impact the out-
come of the disease, using a mapping technic.
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